TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway

Honghong Yao¹, Fuwang Peng¹, Yi Fan², Xuhui Zhu¹, Gang Hu², and Shilpa Buch¹,*
¹Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska
²Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, China.

Abstract
Platelet-derived growth factor-BB (PDGF) has been reported to provide tropic support for neurons in the central nervous system. The protective role of PDGF on dopaminergic neurons, especially in the context of HIV-associated dementia (HAD), however, remains largely unknown. Herein we demonstrate that exogenous PDGF was neuroprotective against toxicity induced by HIV-1 Tat in primary midbrain neurons. Furthermore, we report the involvement of transient receptor potential canonical (TRPC) channels in PDGF-mediated neuroprotection. TRPC channels are Ca²⁺-permeable, nonselective cation channels with a variety of physiological functions. Blocking TRPC channels with either a blocker or short interfering RNAs (specific for TRPC 5 and 6) in primary neurons resulted in suppression of both PDGF-mediated neuroprotection as well as elevations in intracellular Ca²⁺. PDGF-mediated neuroprotection involved parallel but distinct ERK/CREB and PI3K/Akt pathways. TRPC channel blocking also resulted in suppression of PDGF-induced Pyk2/ERK/CREB activation, but not Akt activation. Relevance of these findings in vivo was further corroborated by intrastratal injections of PDGF and HIV-1 Tat in mice. Administration of PDGF was able to rescue the dopaminergic neurons in the substantia nigra from Tat-induced neurotoxicity. This effect was attenuated by pre-treatment of mice with the TRP blocker, thus underscoring the novel role of TRPC channels in the neuroprotection mediated by PDGF.

Keywords
PDGF; dopaminergic neurons; TRPC; Ca²⁺; Pyk2; ERK; CREB; PI3K/Akt

Introduction
Human immunodeficiency virus (HIV) infection selectively targets the basal ganglia region of the brain resulting in loss of dopaminergic neurons, that have been implicated in the
clinical manifestation of HIV-1 associated dementia (HAD) (1, 2). Accordingly, mounting
evidence on the involvement of dopamine impairment in HAD comes from case studies on
pathological specimens of HIV-infected patients demonstrating loss of dopaminergic
neurons (1). Furthermore, experimental studies have also indicated that nigrostriatal neurons
in the basal ganglia are susceptible to HIV-1 protein-mediated toxicity (3). Since there is no
evidence of direct infection of neurons by HIV-1, it is hypothesized that neuronal cell death
is a consequence of the toxic effects of viral and cellular neurotoxins that are released from
virus-infected and/or activated cells (4). One of the potent viral toxins implicated in
neuronal injury/death is the virus transactivator protein, HIV-1 Tat that can be secreted from
infected cells and can be taken up by the neighboring non-infected cells, including neurons
(5). Indeed, HIV-1 Tat is known to inhibit tyrosine hydroxylase (TH) gene expression in
dopaminergic neuronal cells thereby contributing to motor abnormalities observed in HAD
patients (3, 6).

Neuronal homeostasis is maintained by the fine balance between neurotrophic versus
neurotoxic factors. Various neurotrophic factors, such as brain-derived neurotrophic factor
(BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF)
have been implicated in the protection of neurons against neurotoxins (7-9). In the present
study, we explored the role of yet another neurotrophic factor, platelet-derived growth factor
(PDGF) that has been documented to be critical for the development of brains of postnatal
rats (10). PDGF belongs to a family of five dimeric ligands (PDGF-AA, -AB, -BB, -CC and
-DD) assembled from four gene products (PDGF-A-D) that act via two classical receptors
tyrosine kinases (RTKs), PDGF-α receptor (PDGF-αR) and PDGF-β receptor (PDGF-βR).
PDGF-βR has been implicated in neuroprotection following ischemic events in the rat (11).
Members of the PDGF family have multiple roles during embryogenesis and in a variety of
pathological situations in the adult (12). Among these members, PDGF has been
demonstrated to protect primary hippocampal neurons against glutamate-induced neuronal
damage (13). In our previous findings we have reported that PDGF can exert
neuroprotection against the HIV envelope protein-mediated toxicity in SH-SY5Y cells (14,
15). PDGF-βR is known to be expressed in 90% of TH-positive neurons and has been shown
to be involved in TH gene expression and neuronal survival (16). However, whether PDGF
can regulate dopaminergic neurons against HIV protein toxicity remains to be explored.

Neurotrophic family of growth factors is known to be essential for the survival of neurons
(7). The mechanism of action of the neurotrophins on neuron survival is mediated by the
extracellular signal-regulated protein kinase (ERK)/cAMP-response element-binding protein
(CREB) and phosphoinositide-3-kinase (PI3K)/Akt pathways. Additionally, receptors for
the neurotrophins, RTKs, that can stimulate PLC-γ to activate transient receptor potential
canonical channels (TRPC), have also been shown to play a role in neuroprotection (17).
Recent studies have revealed these TRPC channels to be Ca²⁺-permeable, nonselective
cation channels (17). Transient receptor potential (TRP) channels are formed by homomeric
or heteromeric complexes of TRP proteins that constitute at least six subfamilies: TRPC
(TRP-canonical), TRPV (TRP-vanilloid), TRPM (TRP-melastatin), TRPMLs (TRP-
mucolipins), TRPPs (TRP-polyclinists) and TRPA1 (TRP-ankyrin transmembrane protien1)
(18-20). These channels are important in various physiological processes ranging from
sensation to male fertility. PDGF receptor belongs to RTKs, and the mammalian TRPC
channels can be activated by RTKs (18, 21, 22). We thus sought to examine whether TRPC channels were involved in regulating neuronal protection mediated by PDGF and, if so, what were the downstream effectors for TRPC channel activation.

In the present study we demonstrate direct evidence of the neuroprotective action of PDGF against HIV Tat toxicity through two distinct signaling pathways-TRPC/Ca\(^{2+}\)/ERK and PI3K/Akt. Our data support the possibility that PDGF signaling in the midbrain neurons may contribute to the maintenance of neuronal survival.

**Results**

1. **PDGF attenuates HIV-1 Tat cytotoxicity in rat primary midbrain neurons**

In order to examine whether PDGF could abrogate Tat cytotoxicity, rat primary midbrain neurons were first exposed to HIV Tat protein (14 nM) for 24h and cell viability assessed by MTT assay. As shown in Figure 1A, Tat exposure resulted in a decrease in cell viability (32%; p<0.001). Treatment of neuronal cells with either the heat-inactivated or mutant Tat, however, did not exert any cytotoxicity in these cells. We next sought to examine the neuroprotective effect of PDGF against Tat toxicity. Rat neurons were pre-treated with PDGF [20 ng/ml; concentration pre-determined based upon our previous work (14, 15)] for 30 min followed by exposure of cells to Tat protein (14 nM). Twenty hours later cell viability was measured using the MTT assay. As shown in Figure 1B, pre-treatment of cells with PDGF followed by exposure to HIV Tat resulted in increase in cell viability. PDGF alone did increase cell viability, although this effect was not statistically significant compared with control. These findings were also confirmed by immunostaining assay using the anti-microtubule-associated protein-2 (MAP-2) antibody. As shown in Figures 1C & D there was loss of neuronal processes as well as MAP-2 immunoreactivity in the Tat-treated group, an effect that was ameliorated by pre-treatment of cells with PDGF. Cells cultured in the presence of PDGF alone did not demonstrate any change in dendrite length compared with the untreated control cells.

In addition to MAP-2 staining the neuroprotective effects of PDGF were further corroborated by morphological analysis of dopaminergic neurons following immunocytochemical staining of the cells with TH, a characteristic marker of these neurons. As shown in Figure 1E & F, treatment of neuronal cells with HIV-1 Tat resulted in ~40% decrease in the total dendrite length per TH-immunoreactive neuron, pre-treatment of neuronal cultures with PDGF resulted in enhanced TH-immunoreactivity (red fluorescence).

Since HIV Tat mediates neurotoxicity by the programmed cell death pathway, we next sought to examine whether PDGF-mediated protection of neurons involved inhibition of Tat-induced neuronal apoptosis using Annexin-V binding and propidium iodide (PI) uptake. As shown in Figure 1G, there was an increase in Annexin-V positive cells (27.5% versus 15.2%) in Tat-treated cultures compared with control cells as evidenced by flow cytometry. In contrast, PDGF pre-treatment prior to Tat exposure resulted in decreased numbers of apoptotic cells (27.5% versus 20.9% - Tat treated versus PDGF/Tat). The above findings were further confirmed by staining cells with Hoechst 33342, a nuclear dye that stains
nuclei. Pretreatment of neurons with PDGF reduced Tat-induced neuronal apoptosis as quantified in Figure 1H.

2. **PDGF receptor is necessary for PDGF mediated neuroprotection**

Since PDGF mediates signaling through its cognate receptor PDGF-βR, we next sought to examine the expression and phosphorylation pattern of this receptor in rat primary neurons. As shown in Figure 2A, rat primary midbrain neurons expressed PDGF-βR, which was rapidly phosphorylated by treatment of neurons with PDGF as evidenced by Western blot analysis. Furthermore, pre-treatment of cells with the PDGF receptor antagonist STI-571 (1 μM) for 1 h abolished this effect.

We next assessed whether the protective effects of PDGF were mediated via its binding to its cognate PDGF-βR. As shown in Figure 2B receptor tyrosine kinase antagonist STI-571 was able to inhibit PDGF-mediated neuroprotection in rat primary neurons, although not to that of levels with HIV Tat alone. Exposure of neurons to PDGF alone did increase cell viability, although this effect was not statistically significant. In the presence of STI-571, PDGF-mediated increased in cell viability was significantly inhibited. We acknowledge the fact that STI-571 is not a specific antagonist for PDGF-βR, since it is also known to inhibit, PDGF-αR, as well as other kinase activities. Hence as an alternative approach we next sought to knock down PDGF-βR expression in neurons using the short interfering (si) RNA strategy. As shown in Figure 2C, PDGF-βR siRNA abrogated the expression of PDGF-βR in neurons, while also blocking the neuroprotection mediated by PDGF (Figure 2D), thus confirming the role of PDGF-βR in this process.

3. **TRPC channels are required for PDGF-mediated neuroprotection**

Because Ca\(^{2+}\) is known to mediate cell survival and TRPC is a member of TRP superfamily that functions as Ca\(^{2+}\) influx channels, it is possible that Ca\(^{2+}\) influx through TRPC channels is required for the neuroprotection mediated by PDGF in primary midbrain neurons. In order to test this hypothesis, cells were pre-treated with TRP channel blocker and assessed for PDGF-mediated protection against Tat toxicity. As shown in Figure 3A, in neurons pre-treated with the SKF96365 (20 μM), a nonspecific inhibitor of store-operated Ca\(^{2+}\) entry and TRP channels (23, 24), PDGF-mediated neuroprotection against Tat toxicity was inhibited compared with cells not treated with the inhibitor.

In our previous study we have demonstrated that rat primary midbrain neurons express TRPC1, 5 & 6 protein (25). In order to ascertain the TRPC subtype(s) critical for PDGF-mediated neuroprotection, each of the TRPC subtypes (1, 5 or 6) was individually downregulated using the specific siRNAs, followed by assessment of PDGF-induced neuroprotection. As shown in Figure 3B siRNA against TRPC1, 5 & 6 suppressed expression of TRPC 1, 5 & 6, respectively. Interestingly however, TRPC 5 and 6 siRNAs, but not TRPC 1 siRNA alleviated PDGF-mediated neuroprotection (Figure 3C). These findings thus underpin the roles of TRPC 5 & 6 in neuroprotection exerted by PDGF. To further examine the role of TRPC 5 and 6 in PDGF-mediated neuroprotection, we next sought to determine whether TRPC5 and TRPC 6 co-localized with PDGF-βR in primary
midbrain neurons. As shown in Figure 3D, both the TRPC channels co-localized with the PDGF-βR in these cells, thus further validating the role of these channels.

PDGF activates its receptor and stimulates phospholipase C (PLC), resulting in inositol triphosphate (IP3)-dependent release of Ca\(^{2+}\) from intracellular stores and Ca\(^{2+}\) influx from extracellular sources (26). Interference of the PLC-IP3 pathway thus ought to suppress the protection exerted by PDGF. As expected, pretreatment of neurons with the PLC inhibitor U73122 (1 μM) did indeed abolish the neuroprotective action of PDGF against Tat toxicity, while its inactive analog U73343 (1 μM) did not exert this effect. The neuroprotective effect of PDGF also depended on IP3R activation, since exposure of neurons to antagonists specific for IP3 receptor, 2-ApB (100 μM) as well as Xest-C (1 μM), resulted in suppression of PDGF-mediated neuroprotection. Treatment of neurons with OAG (50 μM), a membrane permeable analog of diacylglycerol (DAG), however, did not protect rat primary midbrain neurons against Tat toxicity, suggesting thereby that PLC-DAG pathway was not involved in PDGF-mediated neuroprotection. Taken together, these findings confirmed the role of PLC-IP3R pathway in PDGF-mediated neuronal protection against Tat toxicity.

4. TRPC channels contribute to PDGF-induced intracellular Ca\(^{2+}\) elevations

In order to study the effects of PDGF on the intracellular Ca\(^{2+}\) transients (i) in rat primary midbrain neurons, we first measured PDGF-induced intracellular [Ca\(^{2+}\)]i release using Fluo-4/AM imaging. As shown in Figure 4A & B, exposure of neurons to PDGF triggered a rapid and substantial [Ca\(^{2+}\)]i increase in primary midbrain neurons. This response was inhibited by the PDGF receptor antagonist STI-571 (Figure 4C). Furthermore, this elevation in [Ca\(^{2+}\)]i-induced by PDGF was suppressed by culturing cells in Ca\(^{2+}\)-free medium in the presence of EGTA (2 mM), suggesting thereby that PDGF-induced [Ca\(^{2+}\)]i increase depended on the extracellular Ca\(^{2+}\) influx (Figure 4C).

Since TRPC channels are Ca\(^{2+}\)-permeable cation channels, we next wanted to assess whether PDGF-induced [Ca\(^{2+}\)]i elevations in primary midbrain neurons were mediated by TRPC. To confirm the role of TRPC in PDGF-induced [Ca\(^{2+}\)]i elevations, rat midbrain neurons were pre-treated with the SKF96365 (20 μM) prior to treatment of the cells with PDGF. As shown in Figure 4C cells pre-treated with the SKF96365 demonstrated marked reduction of PDGF-induced elevation of [Ca\(^{2+}\)]i, thus underscoring the role of TRPC in this process. In contrast, the L-type voltage-gated calcium channel blocker nifedipine (10 μM) did not affect PDGF-induced [Ca\(^{2+}\)]i elevation. Having determined the role of specific TRPC proteins in neuroprotection-mediated by PDGF, we next sought to dissect the role of specific TRPC channels in PDGF-induced Ca\(^{2+}\) influx. Similar to our findings of the role of TRPC 5 and 6 in PDGF-mediated Ca\(^{2+}\) influx, TRPC5 & 6 siRNA, but not TRPC 1 siRNA attenuated Ca\(^{2+}\)-influx induced by PDGF (Figure 4D).

Since PDGF/PDGF-βR activation stimulates PLC, the next set of experiments was conducted using the PLC inhibitor U73122 (1 μM). Similar to findings with the SKF96365, neurons pretreated with U73122, failed to demonstrate PDGF-induced [Ca\(^{2+}\)]i elevation (Figure 4C). Interestingly, pretreatment of neurons with the inactive analog of U73122 (U73343) had no effect on PDGF-induced Ca\(^{2+}\) influx. Furthermore, pre-treatment of neurons with the IP3R antagonists 2-ApB and Xest-C resulted in inhibition of PDGF-
induced \([\text{Ca}^{2+}]_i\) elevation. In summary, PDGF-induced \([\text{Ca}^{2+}]_i\) elevation depends on the PLC-IP3R pathway.

5. PDGF-mediated activation of TRPC channels involves amplification of the ERK signal via the Pyk2 pathway

ERK/mitogen-activated protein kinase (MAPK) pathway has been demonstrated to play a crucial role in anti-apoptotic mechanisms. It was therefore of interest to examine the effect of PDGF on ERK activation in rat primary neurons. As shown in Figure 5A, exposure of neurons to PDGF resulted in a sustained and time-dependent activation of ERK, which was blocked by pre-treating cells with both the PDGF-βR antagonist STI-571 as well as the MAPK/ERK kinase (MEK) inhibitor U0126 (20 μM), but not the PI3K inhibitor LY294002 (20 μM) (Figure 5B). The functional role of PDGF-induced ERK activation in mediating neuroprotection was also corroborated using cell viability assays, wherein PDGF failed to exert its protective effect in cells pre-treated with MEK inhibitor, thereby underscoring the role of this pathway in PDGF-mediated neuroprotection (Figure 5C).

Activation of the ERK Pathway is known to be mediated by an upstream signaling molecule - the \([\text{Ca}^{2+}]_i\)-sensitive, proline-rich tyrosine kinase 2 (Pyk2). In our findings we demonstrated PDGF-mediated induction of Pyk2 as early as 5 mins following stimulation of the cells (Figure 5D). In addition to Pyk2, calcium-modulate kinases (CaMKs), another class of \([\text{Ca}^{2+}]_i\) sensitive signaling molecules are also known to play critical roles in cell survival. We thus sought to examine whether PDGF-mediated neuroprotection also involved activation of CaMKs. As shown in Figure 5E PDGF failed to activate either CaMK II or CaMKIV, thereby ruling out the role of these molecules in PDGF-mediated neuroprotection.

Since CREB is a transcriptional factor that lies downstream of ERK and plays an important role in cell survival, we next examined CREB phosphorylation following PDGF treatment using Western blot analysis. As shown in Figure 5F, treatment of neurons with PDGF resulted in increased nuclear CREB phosphorylation that correlated well with a concomitant decrease in cytosolic CREB.

Having determined the role of TRPC channels in PDGF-mediated neuroprotection we next wanted to dissect the role of these channels in PDGF-mediated ERK activation pathway. Pre-treatment of neurons with both the TRP channels blocker SKF96365 (20 μM) and EGTA (2 mM) markedly attenuated PDGF-induced phosphorylation of Pyk2, ERK and CREB (Figure 6A-C). These findings suggested that PDGF-mediated neuroprotection via the TRPC/Ca\(^{2+}\) pathway involves phosphorylation of Pyk2, ERK and CREB signaling molecules.

In order to further confirm the role of specific TRPC protein(s) in PDGF-induced ERK, Pyk2 and CREB phosphorylation, each of the TRPC subtypes (1, 5 or 6) was individually down-regulated using specific short interfering RNAs (siRNA) followed by assessment of PDGF-induced ERK, Pyk2 and CREB phosphorylation. Interestingly, siRNA for both TRPC 5 and 6 decreased PDGF-mediated Pyk2, ERK and CREB phosphorylation (Figure 7A, B & C), whereas TRPC 1 siRNA exerted no such effect. These findings thus underpinned the roles of TRPC 5 & 6 in PDGF-mediated ERK, Pyk2 and CREB phosphorylation.
6. TRPC channels are not required for PDGF-induced Akt activation

In addition to the MEK/ERK pathway, PI3K-Akt pathway also plays a critical role in cell survival. We thus examined the role of the latter pathway in PDGF-mediated neuroprotection. As shown in Figure 8A, following exposure of neurons to PDGF there was an enhanced activation of Akt, which was abrogated by both the PDGF-βR antagonist STI-571 (1 μM) as well as the PI3K inhibitor LY294002 (20 μM) (Figure 8B). We next wanted to assess the functional role of PI3K-Akt in PDGF-mediated neuroprotection against Tat. As shown in Figure 8C, PDGF pretreatment resulted in inhibition of Tat neurotoxicity and this effect was reversed in the presence of PI3K inhibitor LY294002. These results suggested the involvement of PI3K/Akt pathway in PDGF-mediated neuroprotection against HIV Tat. Further confirmation of the involvement of Akt pathway in PDGF-mediated neuroprotection was demonstrated with the use of adenovirus vector constructs encoding a dominant-interfering form of Akt. As shown in Figure 8D, in neurons infected with the dominant interfering form of Akt, PDGF failed to protect against Tat toxicity. Infection of neurons with wild type Akt, on the other hand, resulted in PDGF-mediated neuroprotection as expected.

Having determined that TRPC channels were involved in regulation of ERK/CREB activation, we next wanted to dissect the role of these channels in PDGF-mediated Akt activation pathway. As shown in Figure 8E, pre-treatment of neurons with both the TRP channel blocker SKF96365 as well as EGTA did not attenuate PDGF-induced Akt activation. Furthermore, siRNA for TRPC (s) did not decrease PDGF-mediated Akt phosphorylation (Figure 8F). These findings thus suggested that PDGF-mediated Akt phosphorylation is independent of TRPC.

7. PDGF-mediated protection of dopaminergic neurons against HIV Tat in vivo

To investigate the relevance of PDGF-mediated protection in vivo, the neuroprotective effect of PDGF on dopaminergic neuronal survival was determined in adult mice injected intrastriatally with either saline or PDGF followed by microinjection with HIV-1 Tat. Seven days later mice brains were examined for TH positive neurons in the substantia nigra. As shown in Figure 9A, there was increased neuronal loss in Tat-injected mice as evidenced by decreased TH staining. This effect was ameliorated in mice pre-treated with PDGF as quantified in Figure 9B, indicating that PDGF protected dopaminergic neurons against HIV Tat. Similar to saline injected mice, exposure to PDGF alone had no significant effect on neuronal survival. Furthermore, to confirm the role of TRPC in PDGF-mediated neuroprotection against Tat, we pretreated mice with the TRP channels blocker SKF96365 prior to treatment with PDGF and HIV Tat. Pre-treatment of mice with SKF96365 (0.2 μmol) followed by exposure to PDGF and Tat resulted in attenuation of PDGF-mediated neuroprotection.

Discussion

In this study we demonstrate that in vivo PDGF was able to rescue dopaminergic neurons from HIV Tat neurotoxicity. Confirmation of the neuroprotective role of PDGF against Tat toxicity was also corroborated in vitro in primary cultures of rat midbrain neurons. We
demonstrated a novel role of the Ca\(^{2+}\)-permeable channel TRPC in PDGF-mediated neuroprotection in rat neurons, indicating that exogenous PDGF activated TRPC resulting in amplification of downstream ERK signaling via the Pyk2 pathway, followed by nuclear translocation of CREB and ultimately culminating in neuronal survival.

Nigrostriatal neurons are susceptible to HIV-1 protein-mediated toxicity and HIV Tat is known to inhibit TH gene expression in dopaminergic neurons contributing to motor abnormalities in HAD patients (3). Expression of PDGF-\(\beta\)R in the dopaminergic neurons and its role in neuronal communication and possibly in dopaminergic neurotransmission circuitry has been demonstrated by Othberg et al. (16). In our studies we detected the presence and activation of PDGF-\(\beta\)R in rat primary cultured midbrain neurons. Additionally, using the pharmacological and siRNA approaches we also demonstrated that PDGF-mediated neuroprotection involved activation of PDGF-\(\beta\)R.

A novel finding of this study is the role of TRPC in PDGF-mediated neuroprotection against HIV Tat, thereby lending credence to previous reports indicating the involvement of TRPC signaling in neuroprotection (17, 27). The mammalian TRPC channel family consists of seven members, TRPC1-7, that appear to function as receptor-operated channels, analogous to the TRP channels involved in Drosophila phototransduction (28). With the exception of TRPC2, these channels are widely distributed in the mammalian brain. Consistent with the previous reports demonstrating the co-localization of TRPC (1, 5 & 6) with the dopaminergic neurons in substantia nigra (29-31), our findings also provide evidence that TRPC5/6 were colocalized with PDGF-\(\beta\)R in primary midbrain neurons. The mammalian TRPC channels can be activated by G-protein-coupled receptors and RTKs (18, 21, 22). PDGF-\(\beta\)R belongs to the RTK family and is known to activate PLC, leading to hydrolysis of phosphatidylinositol-4,5-biphosphate into membrane-bound DAG and soluble IP3. Generation of IP3 results in IP3 receptor-mediated release of Ca\(^{2+}\) from intracellular stores as well as Ca\(^{2+}\) influx from outside the cell (26).

PDGF triggers [Ca\(^{2+}\)]\(_i\) transients in neuronal precursor cells (32), however, whether PDGF regulates [Ca\(^{2+}\)]\(_i\) remains unclear. Herein we report that PDGF induces [Ca\(^{2+}\)]\(_i\) elevation through engagement of the PDGF-\(\beta\)R since PDGF receptor antagonist was able to abolish PDGF-mediated [Ca\(^{2+}\)]\(_i\) elevations. Furthermore, the increase of [Ca\(^{2+}\)]\(_i\) induced by PDGF was primarily due to Ca\(^{2+}\) entry through the PLC/IP3-induced Ca\(^{2+}\) release and the TRPC channels. These findings were supported by a pharmacological approach using inhibitors specific for PLC (U73122), IP3R (2ApB and Xest-C) and TRP channels (SKF 96365), all of which effectively blocked PDGF-mediated [Ca\(^{2+}\)]\(_i\) elevations. PDGF-mediated calcium influx from extracellular source was confirmed by EGTA, an extracellular Ca\(^{2+}\) chelator which also blocked PDGF-mediated elevation of [Ca\(^{2+}\)]\(_i\).

Influx of Ca\(^{2+}\) is known to regulate numerous physiological processes through a wide range of target proteins such as ERK, Pyk2 and CREB (33-35), which are essential for neuronal survival. In fact, autophosphorylation of Pyk2 on the conserved tyrosine residues Y 402 (36, 37) has been demonstrated to result in downstream activation of ERK. In the present study, we demonstrated that [Ca\(^{2+}\)]\(_i\) elevations triggered by PDGF through the TRPC channels activated CREB through the Pyk2/ERK pathway. Consistent with the previous reports that
ERK and CREB pathways play a role in neuroprotection (38-40), PDGF-mediated neuroprotection also involved activation of both the ERK and CREB pathways.

The seven TRPC channels are divided into two groups based upon their homology and mechanisms of activation. The present study demonstrated that TRPC 5 & 6, but not TRPC1 were required for PDGF-mediated neuroprotection against Tat toxicity. Previous findings have demonstrated the protective role of TRPC1 in MPTP-induced toxicity in SH-SY5Y cells (31). Recent studies have shed light on the mechanisms underlying the activation of TRPC channels by a growth factor such as BDNF (17). In this study activation of TRPC3 and TRPC6 stimulated two signaling pathways: Ca^{2+}/Ras/MEK/ERK and Ca^{2+}/CaM/CaMK that converged on CREB activation (17).

Our findings also unravel the role of TRPC activation by yet another neuroprotective growth factor PDGF. The mechanism of protection by PDGF however, involved action of ERK as well as the PI3K/Akt pathways, an effect that is consistent with the previous reports demonstrating that PDGF stimulates PI3K/Akt pathways in various other cell types (38-40). ERK pathway can be activated via the PI3K activation or independent of it, depending on the cell type (41). In the present study, PDGF-mediated neuroprotection via ERK activation was independent of PI3K pathway, since PI3K inhibitor failed to inhibit PDGF-mediated ERK phosphorylation. Role of Akt pathway in the neuroprotective effects of PDGF was further confirmed using a dominant-interfering form of Akt. Unlike the TRPC-mediated activation of Pyk2/ERK/CREB, PDGF-mediated activation of Akt was independent of TRPC channel activation.

Consistent with the in vitro study demonstrating the involvement of TRPC in PDGF-mediated neuroprotection, we found that pretreatment of adult mice with PDGF also resulted in rescue of Tat-mediated dopaminergic neuronal loss in the substantia nigra. Interestingly, this effect was attenuated by injecting TRP channel blocker-SKF96365 directly into the striatum. The present study for the first time demonstrates that TRPC channels are involved in PDGF-mediated neuroprotection. These findings lend credence to the previously published reports indicating the role of TRPC channels in granule cell survival (17).

In summary, activation of the PDGF/PDGF-βR axis resulted in stimulation of PLC/IP3 R pathway leading to activation of TRPC channels, which in turn, resulted in elevation of [Ca^{2+}]i transients, culminating in activation of Pyk2/ERK/CREB, but not PI3K/Akt pathway (as shown in Figure 10). PDGF-mediated neuronal survival also involved the parallel PI3K/Akt pathway. Taken together our findings suggest that although the two pathways involved in PDGF-mediated neuroprotection against Tat operate independent of each other, their combined actions are necessary for the observed neuroprotective effect of PDGF. A better understanding of these molecular pathways could be critical for the development of therapeutic strategies against HAD.
Materials and Method

Animals

C57BL/6N mice were purchased from (Charles River Laboratories, Inc., Wilmington, MA). All of animals were housed under conditions of constant temperature and humidity on a 12-h light, 12-h dark cycle, with lights on at 0700 h. Food and water were available ad libitum. All animal procedures were performed according to the protocols approved by the Institutional Animal Care and Use Committee of the University of Kansas Medical Center.

Neuronal culture and treatment

Primary neurons were prepared as described earlier with a few modifications (42). Briefly, midbrain tissues were dissected from embryonic day 13-14 Sprague-Dawley rats and dissociated with a mild mechanical trituration. Dissociated cells were seeded first in DMEM/F12 supplemented with 10% fetal bovine serum. After 1 day, the cultures were supplemented with serum-free neurobasal medium containing B27 (50:1), 2 mM glutamax supplemented with antibiotics (100 U/ml penicillin & 100 μg/ml streptomycin). After 7 days, the initial plating cultures consisted of 90% neuron-specific nuclear-protein immunoreactive neurons of which 3% were TH-positive neurons. Based upon our earlier studies, primary midbrain neurons were treated with PDGF (R & D system; 20 ng/ml) and HIV-1 Tat (UK College of Medicine, Lexington, KY; 14nM) at pre-determined concentrations. Treatment of neurons with pharmacological inhibitors (STI-571: 1 μM; SKF96365: 20 μM; EGTA: 2 mM; U73122: 1 μM; U73343: 1 μM; 2ApB: 100 μM; Xest-C: 1 μM; Nifedipine: 10 μM; U0126: 20 μM; LY294002: 20 μM) involved pretreatment of cells with the respective inhibitors for 1h followed by Tat and/or PDGF exposure.

Surgery and microinjection

Ten week old C57BL/6N were anesthetized with 2.5% isofluorane and placed in a stereotaxic apparatus for cannula implantation. Using the stereotaxic coordinates, AP +0.86mm posterior, ML-1.8mm lateral to midline, and DV -3.5mm to bregma according to Franklin and Paxinos mouse brain atlas. A permanent 26-gauge stainless steel guide cannula (C315G; Plastics One, Roanoke, VA) was implanted into the right striatum. The guide cannula was secured in place using gel adhesive and dental cement applied sequentially to the skull. A 33-gauge stainless steel dummy cannula was used to seal the guide cannula when not in use. After surgery the animals were housed individually to avoid damage to guide and dummy cannula.

Following striatal cannulation animals were allowed to recover for 7 d and were randomly divided into six groups (n=5): Saline, Tat, PDGF alone, PDGF plus Tat, and SKF96365 plus PDGF plus Tat (using two doses of the SKF96365-see below) groups. Tat and PDGF each were injected at a concentration of 1μg per 2μl/mouse/day for two days. Saline control mice were injected with the same volume of sterile saline (2 μl). In the PDGF plus Tat group of mice, PDGF was first microinjected for two days followed by HIV-1 Tat microinjection for subsequent 2 days. To determine the optimal dose of the TRP channel blocker in mice, SKF 96365 freshly dissolved in 0.9% sterile saline, was injected at two different concentrations, (0.02 μmol & 0.2 μmol/2 μl/mouse; concentrations determined from our in vitro study) for 2
consecutive days, followed by PDGF and Tat microinjections. All microinjections were performed using a 33-gauge stainless steel injector connected to a 10 μl syringe which was operated by an infusion pump set at the rate of 0.4 μl/min. An additional minute was allowed for diffusion and prevention of backflow through the needle track before the injector was withdrawn. Histological verification of the striatum cannula was performed at the end of each experiment.

**Cell survival**

The percentage of surviving neurons in the presence of PDGF and/or HIV-1 Tat was estimated using the biochemical and histological analyses listed below.

**MTT**

Cell viability was measured by mitochondrial dehydrogenases [3(4,5-dimethylthiazol-2-yl)-2.5 diphenyltetrazolium bromide] (MTT) method. Primary midbrain neurons were seeded in 96-well plates at a density of 10^5 cells/cm^2 for 7 days, following which neurons were exposed to fresh medium containing various concentrations of PDGF for 20 min at 37°C. Subsequently, HIV-1 Tat (14 nM) was added into the medium and cells were continued to incubate for another 24 h [concentration pre-determined from our previous work] (25). After incubation for up to 24 h, 20 μl MTT tetrazolium salt dissolved in Hank's balanced salt solution at a final concentration of 5 mg/ml was added to each well and incubated in the CO2 incubator for 4 h. Finally, the medium was aspirated from each well and 200 μl of DMSO was added to dissolve the formazan crystals and the absorbance of each well was obtained using a Dynatech MR5000 plate counter at test and reference wavelengths of 570 and 630 nm, respectively.

**Hoechst staining**

To quantify apoptotic neurons, neurons were fixed and stained with Hoechst 33324 (Sigma, St Louis, MO, USA). The morphological features of apoptosis (cell shrinkage, chromatin condensation, and fragmentation) were monitored by fluorescence microscopy (Olympus BX 60, Tokyo, Japan). At least 400 cells from 12 randomly selected fields per dish were counted, and each treatment was performed in triplicate.

**Flow cytometry**

Neuronal apoptosis was estimated using the Annexin-V Fluorescein (FITC) apoptosis detection kit (Oncogene Research Products, San Diego, CA, USA) according to the manufacturer's instructions. The cell samples were analyzed in a flow cytometry apparatus (Becton Dickinson FACSVantage SE, San Jose, CA, USA). Annexin V binds to phosphatidylserine that is translocated during apoptosis from the inner to the outer leaflet of the plasma membrane. Live cells with intact membranes are distinguished by their ability to exclude propidium iodide, which readily penetrates dead or damaged cells. Dual analysis was introduced using a quadrant dot plot, in which necrotic cells were identified as single PI-positive, early apoptotic cells were Annexin V-FITC-positive only, and cells in late apoptosis were recognized as double-positive for annexin V-FITC and propidium iodide. Cells that stained negative for both annexin V-FITC and PI were classified as live cells.
Finally, the number of cells in each category was expressed as a percentage of the total number of stained cells counted.

**Analyses of neuronal dendrites**

Primary rat midbrain neurons were stained with anti-MAP-2 antibody and dopaminergic neurons were identified with the anti-TH as described previously with minor modifications (43). For the measurement of the dendrite length, images of individual MAP-2/TH-positive neurons were recorded. The length of each fiber originating from each neuronal cell body and subsequent branches was measured, and a sum of total dendrite length for each neuron was calculated using Image Pro-plus software. For each well, 50 neurons were analyzed for total dendrite length. Results were expressed as a percentage of the control cultures using a Nikon TE2000E microscope with a digital camera (Photometrics, Tucson, AZ) (43).

**Measurement of [Ca^{2+}]i**

The changes in [Ca^{2+}]i were monitored using Fluo-4/AM dissolved in dimethyl sulfoxide. The rat midbrain neurons in 35-mm culture dishes were rinsed twice with Physiological Solution (PS, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 10 mM glucose, 5.5 mM HEPES, pH 7.4) followed by incubation in PS containing 5 μM Fluo-4/AM (Molecular Probes, Eugene, OR) at 37°C for 40 minutes. Cells were then rinsed twice with the PS, mounted on a perfusion chamber, and scanned every second using confocal microscopy (Fluoview 300; Olympus). Fluorescence excitation at 488 nm was provided by an argon laser, and the emitted light (515 nm) captured along with transmitted images. All analyses of [Ca^{2+}]i were processed at a single-cell level and are expressed as the relative fluorescence intensity. For ratiometric analysis, cells were loaded (using procedures described above) with Fluo-4 and Fura-Red. Fluorescence values from subcellular regions were calculated as mean pixel values ± SE, and a ratio was calculated by using the Fluo-4/Fura Red combination. All of these studies were done at least 4 times.

**Western blotting**

Treated cells were lysed using the Mammalian Cell Lysis kit (Sigma, St. Louis, MO) and the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL). Equal amounts of the corresponding proteins were electrophoresed in a sodium dodecyl sulfate-polyacrylamide gel in reducing conditions followed by transfer to PVDF membranes. The blots were blocked with 5% non fat dry milk in phosphate buffered saline. The western blots were then probed with antibodies recognizing the phosphorylated forms of PDGF-βR, ERK1/2, Pyk2, Akt, CREB (Cell Signaling, Danvers, MA 1:200), and β-actin (Sigma, St. Louis, MO, 1:4000) The secondary antibodies were alkaline phosphatase conjugated to goat anti mouse/rabbit IgG (1:5000). Signals were detected by chemiluminescence (Pierce). All of Western blot was repeated at least three times.

**Co-immunoprecipitation**

The procedure for immunoprecipitation was performed as described previously (15). Briefly, rat primary neurons were treated with PDGF &/ or PDGF-receptor antagonist STI-571 or siRNAs followed by lysis in RIPA buffer (50 mm Tris, pH 8.0, 150 mm NaCl,
0.1% SDS, 1.0% NP-40 and 0.5% sodium deoxycholate) containing proteinase and phosphatase inhibitors. For each sample, 200 μg of protein was used for coimmunoprecipitation. The sample protein was incubated with 2 μg diluted anti-4-G-10 or Pyk2 antibody (Upstate or Cell signaling) overnight at 4 °C followed by incubation with 20 μl of protein A-sepharose for 3h at 4°C. The mixture was then centrifuged (at 6000 g for 30 s) and the cell pellets were rinsed twice with RIPA, followed by boiling in 2X Western blot loading buffer for 4 min. After spinning (at 6000 g for 30s) the supernatants were subjected to Western blot as described above.

**Adenovirus infection**

Primary midbrain neurons were infected with adenoviral constructs containing the WT or dominant-interfering forms of Akt (kind gift from Dr. K Walsh). Neurons infected for 48h with adenovirus constructs were subsequently treated with Tat and/or PDGF followed by assessment of cell survival as described above.

**Short Interfering (si) RNA transfection**

siRNA targeted against PDGF-β R were obtained from Thermo Scientific Dharmacon RNAi Technologies (Accell SMART Pool, Cat# E-091874-00). siRNAs targeted against TRPC1, 5 and 6 were obtained from Ambion (Austin, TX). The sequences of these siRNAs are in listed in Table 1. For siRNA transfection, we used the rat Neuron Nucleofector Kit (Amaxa, Gaithersburg, MD) according to the manufacturer’s instructions. Briefly, dissociated cells were re-suspended in transfection medium, mixed with the respective siRNAs (200 nM), and electroporated using the fixed program (O-03) for optimal neuronal transfection. Cells were then quickly centrifuged, resuspended and plated. The knockdown efficiency of siRNAs was determined after 7 days of transfection by Western blotting.

**Immunocytchemistry**

For immunocytochemistry primary midbrain neurons were plated on cover slips. After 7 days, cells were fixed with 4% paraformaldehyde for 15 min at room temperature followed by permeabilization with 0.3% Triton X-100 in PBS. Cells were then incubated with a blocking buffer containing 10% NGF in PBS for 1h at room temperature followed by addition of rabbit anti-TRPC5&6 (1:100; Alomone Lab, Jerusalem, Israel) and mouse anti-PDGF-βR (1:500; Cell Signalling) antibodies and incubated overnight at 4°C. Finally, the secondary AlexaFluor 488 goat anti-rabbit IgG and AlexaFluor 569 goat anti-mouse IgG, was added at a 1:500 dilution for 2h to detect TRPC and PDGF-βR. Cells were washed 3 times in buffer and mounted with Vectashield onto slides (Vector Laboratories, Burlingame, CA). Confocal images were taken at a magnification of 60×(objective lens) with an Eclipse C1 Plus confocal microscope (Nikon).

For immunohistochemistry mice were perfused by transcardial perfusion using chilled 4% paraformaldehyde. Free-floating sections encompassing the entire midbrain were sectioned at 40 μm on a cryostat. For TH immunostaining, tissue sections were incubated with primary antibodies overnight at 4°C. Primary antibodies used in this study were as follows: rabbit anti-TH (1:4000, Sigma, USA). Immunostaining was visualized by using 3, 3'
diaminobenzidine as the substrate. Quantitative (neuronal number) estimates of TH positive cell bodies were performed ipsilaterally in the areas of interest using stereology method.

**Statistical analysis**

Data were expressed as mean ± SEM. Significance of differences between control and samples treated with various drugs was determined by one-way ANOVA followed by post hoc least significant difference (LSD) test. Values of p < 0.05 were taken as statistically significant.

**Acknowledgement**

We thank from Dr. K Walsh (Tufts University School of Medicine) for providing adenoviral constructs for the WT and dominant-interfering forms of Akt. We thank Dr. Y Jia (Jackson Laboratory) for technical support with siRNA TRPC. This work was supported by grants MH-068212, DA020392, DA023397 and DA024442 from the National Institutes of Health (SB).

**Abbreviations**

- **BDNF**: brain-derived neurotrophic factor
- **CaMKs**: calcium-modulate kinases
- **CREB**: cAMP-response element-binding protein
- **DAG**: diacylglycerol
- **ERK**: extracellular signal-regulated protein kinase
- **GDNF**: glial cell line-derived neurotrophic factor
- **HIV-1**: human immunodeficiency virus-1
- **HAD**: HIV-1 associated dementia
- **IP3**: inositol triphosphate
- **MAP-2**: microtubule-associated protein-2
- **MAPK**: mitogen-activated protein kinase
- **MTT**: 3(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
- **TH**: tyrosine hydroxylase
- **MEK**: MAPK/ERK kinase
- **NGF**: nerve growth factor
- **PI**: propidium iodide
- **PI3K**: phosphoinositide-3-kinase
- **PDGF**: platelet-derived growth factor
- **PLC**: phospholipase C
- **Pyk2**: proline-rich tyrosine kinase 2
- **TRP**: transient receptor potential
References

1. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol. 2000; 14(3):222–227. [PubMed: 11106300]

2. Mocchetti I, Nosheny RL, Tanda G, Ren K, Meyer EM. Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci. Dec. 2007 1122:144–154. [PubMed: 18077570]

3. Zauli G, Secchiere P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, et al. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. Feb 11; 2000 275(6):4159–4165. [PubMed: 10660577]

4. Eugenin EA, D’Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. Jun; 2003 85(5):1299–1311. [PubMed: 12753088]

5. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med. Dec; 2000 6(12):1380–1387. [PubMed: 11100124]

6. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res. Oct; 2005 8(1-2):51–61. [PubMed: 16260385]

7. Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. Oct; 2005 12(10):1329–1343. [PubMed: 15905876]

8. Arthur DB, Georgi S, Akassoglou K, Insel PA. Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival. J Neurosci. Apr 5; 2006 26(14):3798–3804. [PubMed: 16597733]

9. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol. Aug; 2008 85(4):407–432. [PubMed: 18586376]

10. Smits A, Kato M, Westermark B, Nister M, Heldin CH, Funa K. Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF. Proc Natl Acad Sci U S A. Sep 15; 1991 88(18):8159–8163. [PubMed: 1654560]

11. Egawa-Tsuzuki T, Ohno M, Tanaka N, Takeuchi Y, Uramoto H, Faigle R, et al. The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. Exp Neurol. Mar; 2004 186(1):89–98. [PubMed: 14980813]

12. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. May 15; 2008 22(10):1276–1312. [PubMed: 18483217]

13. Beazely MA, Lim A, Li H, Trepanier C, Chen X, Sidhu BR, et al. Platelet-derived growth factor selectively inhibits NR2B-containing NMDA receptors in cal1 hippocampal neurons. J Biol Chem. Dec 23.2008

14. Peng F, Dhillon N, Cullen S, Yao H, Bokhari S, Zhu X, et al. Platelet-derived growth factor protects neurons against gp120-mediated toxicity. J Neurovirol. Jan; 2008 14(1):62–72. [PubMed: 18300076]
15. Peng F, Dhillon NK, Yao H, Zhu X, Williams R, Buch S. Mechanisms of platelet-derived growth factor-mediated neuroprotection—implications in HIV dementia. Eur J Neurosci. Oct; 2008 28(7): 1255–1264. [PubMed: 18973553]

16. Othberg A, Odin P, Ballagi A, Ahgren A, Funan K, Lindvall O. Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro. Exp Brain Res. 1995; 105(1):111–122. [PubMed: 7589308]

17. Jia Y, Zhou J, Tai Y, Wang Y. TRPC channels promote cerebellar granule neuron survival. Nat Neurosci. May; 2007 10(5):55–56. [PubMed: 17396124]

18. Clapham DE. TRP channels as cellular sensors. Nature. Dec 4; 2003 426(6966):517–524. [PubMed: 14654832]

19. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell. Mar 8; 2002 108(5):595–598. [PubMed: 11893331]

20. Clapham DE, Julius D, Montell C, Schultz G. International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels. Pharmacol Rev. Dec; 2005 57(4):427–450. [PubMed: 16382100]

21. Ambudkar IS, Ong HL. Organization and function of TRPC channelosomes. Pflugers Arch. Nov; 2007 455(2):187–200. [PubMed: 17486362]

22. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol. 2006; 68:619–647. [PubMed: 16460286]

23. Merritt JE, Armstrong WP, Benham CD, Hallam TJ, Jacob R, Jaxa-Chamiec A, et al. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J. Oct 15; 1990 271(2):515–522. [PubMed: 2173565]

24. Zhu X, Jiang M, Birnbaumer L. Receptor-activated Ca2+ influx via human Trp3 stably expressed in human embryonic kidney (HEK)293 cells. Evidence for a non-capacitative Ca2+ entry. J Biol Chem. Jun 2; 1998 273(1):133–142. [PubMed: 9417057]

25. Yao H, Peng F, Dhillon N, Callen S, Bokhari S, Steno-Bittel L, et al. Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J Neurosci. Feb 11; 2009 29(6):1657–1669. [PubMed: 19211873]

26. White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A. Sep 27; 2005 102(39):14092–14097. [PubMed: 16174730]

27. Bollimuntha S, Singh BB, Shavali S, Sharma SK, Ebadi M. TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem. Jan 21; 2005 280(3):2132–2140. [PubMed: 15542611]

28. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci. Jun; 2001 2(6):387–396. [PubMed: 11389472]

29. De March Z, Giampa C, Patassini S, Bernardi G, Fusco FR. Cellular localization of TRPC5 in the substantia nigra of rat. Neurosci Lett. Oct 10; 2006 402(1-2):35–39. [PubMed: 16635549]

30. Martorana A, Giampa C, De March Z, Viscomi MT, Patassini S, Sancesario G, et al. Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study. Eur J Neurosci. Aug; 2006 24(3):732–738. [PubMed: 16930403]

31. Bollimuntha S, Ebadi M, Singh BB. TRPC1 protects human SH-SY5Y cells against salsolinol-induced cytotoxicity by inhibiting apoptosis. Brain Res. Jul 12; 2006 1099(1):141–149. [PubMed: 16765919]

32. Cuddon P, Bootman MD, Richards GR, Smith AJ, Simpson PB, Roderick HL. Methacholine and PDGF activate store-operated calcium entry in neuronal precursor cells via distinct calcium entry channels. Biol Rev. 2008; 83(2):183–195. [PubMed: 18949136]

33. Agell N, Bachs O, Rocamora N, Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. Aug; 2002 14(8):649–654. [PubMed: 12020764]

34. Fukuchi M, Tabuchi A, Tsuda M. Transcriptional regulation of neuronal genes and its effect on neural functions: cumulative mRNA expression of PACAP and BDNF genes controlled by calcium and cAMP signals in neurons. J Pharmacol Sci. Jul; 2005 98(3):212–218. [PubMed: 16006741]
35. Yamamoto S, Shimizu S, Kiyonaka S, Takahashi N, Wajima T, Hara Y, et al. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat Med. Jul; 2008 14(7):738–747. [PubMed: 18542050]

36. Ivankovic-Dikic I, Gronroos E, Blaukat A, Barth BU, Dikic I. Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins. Nat Cell Biol. Sep; 2000 2(9):574–581. [PubMed: 10980697]

37. Girault JA, Costa A, Derkinderen P, Studler JM, Toutant M. FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Trends Neurosci. Jun; 1999 22(6):257–263. [PubMed: 10354603]

38. Kim SY, Bae JC, Kim JY, Lee HL, Lee KM, Kim DS, et al. Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport. Dec 20; 2002 13(18):2483–2486. [PubMed: 12499853]

39. Sodhi A, Biswas SK. Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation. J Interferon Cytokine Res. May; 2002 22(5):517–526. [PubMed: 12060490]

40. Jimenez-Sainz MC, Fast B, Mayor F Jr, Aragay AM. Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol. Sep; 2003 64(3):773–782. [PubMed: 12920215]

41. Heo JS, Han HJ. ATP stimulates mouse embryonic stem cell proliferation via protein kinase C, phosphatidylinositol 3-kinase/Akt, and mitogen-activated protein kinase signaling pathways. Stem Cells. Dec; 2006 24(12):2637–2648. [PubMed: 16916926]

42. Yao HH, Ding JH, Zhou F, Wang F, Hu LF, Sun T, et al. Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. J Neurochem. Feb; 2005 92(4):948–961. [PubMed: 15686497]

43. Zhou F, Yao HH, Wu JY, Yang YJ, Ding JH, Zhang J, et al. Activation of Group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake. J Neurosci Res. Aug 1; 2006 84(2):268–277. [PubMed: 16752416]
Figure 1. PDGF exerts neuroprotection against Tat toxicity
(A) Effect of HIV Tat on the cell survival of rat primary midbrain neurons using the MTT assay. (B) PDGF protects rat primary midbrain neurons against Tat neurotoxicity using the MTT assay. (C) Immunostaining of rat primary midbrain neurons treated with Tat &/or PDGF for 24 h with anti-MAP-2 antibody. Scale bar: 50 μm. (D) Densitometric scan of neuritis (from panel C) expressed as a ratio of neurite length/neuron. (E) Immunostaining of rat primary midbrain neurons treated with Tat &/or PDGF using anti-TH-Ab. Scale bar: 50 μm. (F) Densitometric scan of neuritis (from panel E) using the same method as in (D). Rat primary midbrain neurons treated with Tat &/or PDGF were stained for apoptosis marker Annexin V-FITC using flow cytometric analysis. (G) Hoechst 33342 staining monitored by fluorescence microscopy. (H) Quantification of Annexin V-positive (G) and Hoechst-positive (H) cells as the percentage of total cells. All the data in these figures are presented as mean±SEM of four individual experiments. **p<0.01; ***p<0.001 vs control group; #p<0.05; ##p<0.01 vs Tat (14 nM) group.
Figure 2. PDGF-βR is critical for PDGF-mediated neuroprotection

PDGF receptor antagonist blocked PDGF-βR phosphorylation induced by PDGF as determined by co-immunoprecipitation (A) and also significantly inhibited PDGF-mediated neuroprotection (B). The data are presented as mean±SEM of four individual experiments. **p<0.01 vs control group; ##p<0.01 vs Tat-treated group; +p<0.05 vs both PDGF & Tat treated group; ^p<0.05 vs both PDGF alone treated group. (C) Western blot analysis of whole cell lysates from rat primary midbrain neurons transfected with siRNAs against PDGF-βR or nonsense (Non) siRNA, using antibodies specific for PDGF-βR. Data are representative of three independent experiments. (D) Transfection of rat primary midbrain neurons with siRNAs specific for PDGF-βR or nonsense (Non) siRNA abolished PDGF-mediated neuroprotection. The data are presented as mean±SEM of four individual experiments. **p<0.01 vs control group; ##p<0.01 vs Tat-treated group; +p<0.05 vs both PDGF & Tat treated group.
Figure 3. TRPC channels are required for PDGF-mediated neuroprotection

(A) Cell viability of rat primary neurons exposed to Tat &/or PDGF in the absence or presence of indicated drugs. (SKF96365: 20 μM; EGTA: 2 mM; 2ApB: 100 μM; Xest-C: 1 μM; U73122: 1 μM; U73343: 1 μM; OAG: 50 μM). All the data in these figures are presented as mean ± SEM of four individual experiments. **p<0.01 vs control group; ##p<0.01 vs Tat-treated group; +p<0.05; ++p<0.01 vs both PDGF & Tat treated group. (B) Western blot analysis of whole cell lysates from rat primary midbrain neurons transfected with siRNAs against TRPC1, 5, 6 or nonsense (Non) siRNA using antibodies specific for either TRPC1, 5 or 6. Data are representative of three independent experiments. (C) Rat primary neurons transfected with TRPC1, 5 or 6 siRNAs were monitored for PDGF-mediated cell viability. The data are presented as mean±SEM of four individual experiments. ***p<0.001 vs control group; ##p<0.01 vs Tat-treated group; ++p<0.01, +++p<0.001 vs both PDGF & Tat treated group. (D) Co-localization of TRPC5/6 and PDGF-βR in rat primary midbrain neuronal cultures. Midbrain neurons grown for 10 days were double-stained for TRPC5/6 (green) and PDGF-βR (red). DAPI was the nuclei counter stain (blue). Confocal images were taken at a magnification of 60 × (objective lens) with an Eclipse C1 Plus confocal microscope (Nikon). Scale bar: 50 μm.
Figure 4. TRPC channels contribute to PDGF-induced intracellular Ca\textsuperscript{2+} elevations
(A) Rat primary neurons loaded with Fluo-4 [Ca\textsuperscript{2+}]i sensitive fluorophores before and after PDGF treatment were recorded within a single field using a Fluoview 300 confocal microscope (left panel, numbers in the panels indicate time in seconds) and differential interference contrast (right panel). Scale bar: 100\mu m. (B) Changes in intracellular [Ca\textsuperscript{2+}]i levels in neurons following PDGF treatment were measured using the Fluo-4/Fura Red ratio, and the change in ratio is illustrated from a typical neuron. (C) Changes in fluorescence amplitude (Fluo-4/Fura Red) in rat primary neurons exposed to PDGF in the absence or presence of the indicated drugs (STI-571: 1 \mu M; SKF96365: 20 \mu M; EGTA: 2 mM; 2ApB: 100 \mu M; Xest-C: 1 \mu M; U73122: 1 \mu M; U73343: 1 \mu M; Nifedipine: 10 \mu M). All the data in these figures are presented as mean±SEM of four individual experiments. ***p<0.001 vs control group; ###p<0.001 vs Tat-treated group. (D) PDGF-mediated calcium influx in rat primary neurons transfected with either TRPC1, 5 or 6 siRNA. The data are presented as mean±SEM of four individual experiments. ***p<0.001 vs control group; ###p<0.001 vs PDGF-treated group.
Figure 5. PDGF-induced neuroprotection involves activation of ERK
(A) PDGF induced time-dependent and sustained phosphorylation of ERK. (B) PDGF maintained increased phosphorylation of ERK for at least 1 h, and this effect was abolished by PDGF receptor antagonist STI-571, MEK inhibitor U0126 but not by PI3-K inhibitor LY294002; STI: STI-571; LY: LY294002. (C) Pretreatment of neurons with MEK inhibitor U0126 (20 μM) for 1 h significantly attenuated the protective effect of PDGF. Data are presented as mean ± SEM of four individual experiments. ***p<0.001 vs control group; #p<0.05 vs Tat-treated group; *p<0.05 vs both PDGF & Tat treated group. PDGF exposure resulted in increased time-dependent phosphorylation of Pyk2 (D), but not of CaMKII and CaMKIV (E) in rat primary neurons. PDGF exposure resulted in increased time-dependent phosphorylation of CREB in the nuclear fraction with a concomitant decrease in the cytosolic fraction in rat primary neurons (F).
Figure 6. TRPC channels are critical for PDGF-induced ERK/CREB activation
Rat primary neurons exposed to PDGF in the presence of TRPC blocker and EGTA were monitored for PDGF-mediated ERK, Pyk2 and CREB activation (A-C; upper panels). Densitometric analysis of pERK/ERK, pPyk2/Pyk2 and pCREB/CREB from a representative immunoblot is presented (A-C; lower panels). Data are presented as mean ± SEM of four individual experiments. *p<0.05; **p<0.01 vs control group; #p<0.05, ##p<0.01 vs PDGF group.
**Figure 7. TRPC5 & 6 are essential for PDGF-mediated phosphorylation of Pyk2, ERK and CREB**

Effect of TRPC1, 5 or 6 suppression on PDGF-mediated phosphorylation of ERK, Pyk2 & CREB in rat primary neurons (A-C; upper panels). Densitometric analyses of PDGF-mediated phosphorylation of ERK, Pyk2 and CREB in the presence or absence of siRNAs (A-C; lower panels). Data are presented as mean ± SEM of three individual experiments. *p<0.05; **p<0.01; ***p<0.001 vs control group; #p<0.05, ##p<0.01 vs PDGF with nonsense siRNA group.
Figure 8. TRPC channels are not critical for PDGF-induced Akt activation

(A) PDGF induced time-dependent activation of Akt. (B) PDGF maintained sustained phosphorylation of Akt for at least 1 h and this effect was attenuated by both the PDGF receptor antagonist STI-571 and PI3-K inhibitor LY294002. (C) Pretreatment of neurons with LY294002 (20 μM) for 1 h resulted in inhibition of PDGF-mediated protection using MTT analysis. Data are presented as mean ± SEM of four individual experiments. ***p<0.001 vs control group; #p<0.05 vs Tat-treated group; +p<0.05 vs both PDGF & Tat treated group. (D) Infection of neurons with the dominant-interfering Akt (DN-Akt) resulted in abrogation of PDGF-mediated neuroprotection. Infection with WT Akt (WT-Akt) construct had no effect on cell survival. Data are presented as mean ± SEM of four individual experiments. *p<0.05 vs adenovirus alone group; ##p< 0.01 vs Tat-treated group. (E) Rat primary neurons exposed to PDGF in the presence of absence of TRP blocker and EGTA was monitored for PDGF-mediated Akt activation (upper panel). Densitometric analyses of pAkt/Akt from the representative immunoblots is presented (lower panel). Data are presented as mean ± SEM of four individual experiments. ***p<0.001 vs control group. (F) Rat primary neurons transfected with TRPC1, 5 or 6 siRNAs were monitored for PDGF-mediated Akt phosphorylation (upper panel). Densitometric analyses of PDGF-mediated phosphorylation of Akt in rat neurons depleted of TRPC1, 5 or 6 from a representative immunoblot (lower panel). Data are presented as mean ± SEM of three individual experiments. *p<0.05; **p<0.01 vs control group.
Figure 9. PDGF protects dopaminergic neurons against Tat-induced in the substantia nigra
Representative mesencephalic sections from different groups of mice treated with PDGF and/or HIV Tat in the presence or absence of TRPC blocker SKF96365 were examined for TH positive neurons counted by stereology. There was increased loss of TH-positive neurons in the substantia nigra of Tat alone treated group of mice compared with the saline controls. Pre-treatment with PDGF resulted in amelioration of Tat toxicity in the substantia nigra neurons, and this effect was significantly attenuated in mice pre-treated with SKF 96365 (0.2 μmol). *p<0.05 vs saline group; #p<0.05 vs Tat; +p<0.05 vs PDGF+Tat. SN: Substantia Nigra. Scale bar: 300μm. SKF:SKF 96365 (0.2 μmol).
Figure 10. Schematic illustration demonstrating putative signaling pathways involved in PDGF-mediated neuroprotection in rat primary neurons
PDGF-mediated engagement of the PDGF-β receptor stimulates the PLC/IP3 R pathway, which in turn, activates TRPC channels resulting in elevation of [Ca\textsuperscript{2+}]i transients. [Ca\textsuperscript{2+}]i elevation in turn results in activation of Pyk2/ERK pathways leading to CREB activation and consequently neuronal survival. In addition to this, PDGF/PDGF-βR axis can also activate another distinct pathway - PI3K/Akt, which can also lead to potentiation of neuronal survival.
### Table 1

siRNA sequences of rat TRPC1, 5 & 6

| Items   | Direction | Sequence          |
|---------|-----------|-------------------|
| TRPC1 siRNA | Sense     | CCAUAACAUUGAAAAACGAtt |
|         | Antisense | UCGUUUUCAAUAGUUAUGGta |
| TRPC5 siRNA | Sense     | CACUCUUCGCAUAUCGAAtt |
|         | Antisense | UUCGAUAUCGCAAGAGUGct |
| TRPC6 siRNA | Sense     | CAUACAUGUUUAAUGUACAtt |
|         | Antisense | UGAUCAUAACAAUGUAGUAGct |
| Non     | Sense     | UUCUCCGAACGUGUCACGUsdt |
|         | Antisense | ACGUAGACGUUUCGGAGAAdt |